Free Trial

Avacta Group (AVCT) Competitors

Avacta Group logo
GBX 32.82 -0.93 (-2.76%)
As of 04/4/2025 11:53 AM Eastern

AVCT vs. SLN, PRTC, OXB, HZD, FARN, VRP, ARIX, 4BB, CIR, and BVXP

Should you be buying Avacta Group stock or one of its competitors? The main competitors of Avacta Group include Silence Therapeutics (SLN), PureTech Health (PRTC), Oxford Biomedica (OXB), Horizon Discovery Group plc (HZD.L) (HZD), Faron Pharmaceuticals Oy (FARN), Verona Pharma plc (VRP.L) (VRP), Arix Bioscience (ARIX), 4basebio (4BB), Circassia Group (CIR), and Bioventix (BVXP). These companies are all part of the "biotechnology" industry.

Avacta Group vs.

Silence Therapeutics (LON:SLN) and Avacta Group (LON:AVCT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk, community ranking and dividends.

Avacta Group received 9 more outperform votes than Silence Therapeutics when rated by MarketBeat users. However, 68.81% of users gave Silence Therapeutics an outperform vote while only 67.30% of users gave Avacta Group an outperform vote.

CompanyUnderperformOutperform
Silence TherapeuticsOutperform Votes
203
68.81%
Underperform Votes
92
31.19%
Avacta GroupOutperform Votes
212
67.30%
Underperform Votes
103
32.70%

Silence Therapeutics has a net margin of 0.00% compared to Avacta Group's net margin of -114.45%. Silence Therapeutics' return on equity of 0.00% beat Avacta Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Silence TherapeuticsN/A N/A N/A
Avacta Group -114.45%-74.00%-21.80%

In the previous week, Avacta Group had 1 more articles in the media than Silence Therapeutics. MarketBeat recorded 1 mentions for Avacta Group and 0 mentions for Silence Therapeutics. Avacta Group's average media sentiment score of 0.84 beat Silence Therapeutics' score of 0.00 indicating that Avacta Group is being referred to more favorably in the news media.

Company Overall Sentiment
Silence Therapeutics Neutral
Avacta Group Positive

10.2% of Avacta Group shares are held by institutional investors. 32.9% of Avacta Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Silence Therapeutics has higher earnings, but lower revenue than Avacta Group. Avacta Group is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Silence Therapeutics£11.35M0.00N/A-£48.60N/A
Avacta Group£26.29M4.74-£30.08M-£7.77-4.22

Summary

Avacta Group beats Silence Therapeutics on 8 of the 12 factors compared between the two stocks.

Remove Ads
Get Avacta Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for AVCT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AVCT vs. The Competition

MetricAvacta GroupBiotechnology IndustryMedical SectorLON Exchange
Market Cap£124.69M£117.03M£5.26B£2.43B
Dividend Yield3.97%3.69%4.89%4.94%
P/E Ratio-4.223.1821.38127.39
Price / Sales4.743,975.57355.32261,764.23
Price / Cash15.0013.0138.1828.23
Price / Book2.2334.216.234.34
Net Income-£30.08M-£89.03M£3.21B£5.84B
7 Day Performance-16.82%-4.83%-8.47%2.05%
1 Month Performance-8.32%58.17%-4.87%0.18%
1 Year Performance-37.49%78.63%2.54%23.16%

Avacta Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AVCT
Avacta Group
N/AGBX 32.82
-2.8%
N/A-33.8%£124.69M£26.29M-4.22120
SLN
Silence Therapeutics
N/AN/AN/AN/A£480.35M£11.35M-11.01100High Trading Volume
PRTC
PureTech Health
1.2463 of 5 stars
GBX 147
+2.4%
GBX 455
+209.5%
-41.7%£441.56M£521,320.79-6.03300News Coverage
OXB
Oxford Biomedica
N/AGBX 296.50
-0.8%
GBX 560
+88.9%
+29.8%£315.18M£98.31M-2.20891Positive News
High Trading Volume
HZD
Horizon Discovery Group plc (HZD.L)
N/AN/AN/AN/A£302.98M£54.63M-33.55416
FARN
Faron Pharmaceuticals Oy
N/AGBX 207.60
-2.5%
N/A+50.7%£278.71MN/A-5.5534
VRP
Verona Pharma plc (VRP.L)
N/AN/AN/AN/A£228MN/A-1.6822Gap Up
ARIX
Arix Bioscience
N/AN/AN/AN/A£183.73M£14.16M1,290.919
4BB
4basebio
2.396 of 5 stars
GBX 1,150
+1.8%
GBX 1,600
+39.1%
+32.4%£147.32M£311,000.00-1,474.36101Insider Trade
News Coverage
High Trading Volume
CIR
Circassia Group
N/AN/AN/AN/A£142.66M£27.90M3,400.00111Gap Down
BVXP
Bioventix
N/AGBX 2,400
-0.8%
N/A-47.3%£125.67M£13.65M15.5212Earnings Report
Dividend Cut
High Trading Volume
Remove Ads

Related Companies and Tools


This page (LON:AVCT) was last updated on 4/5/2025 by MarketBeat.com Staff
From Our Partners